We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of ONO-2506PO in Patients With Alzheimer's Disease

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00083421
First Posted: June 18, 2004
Last Update Posted: June 13, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Ono Pharmaceutical Co. Ltd ( Ono Pharma USA Inc )
  Purpose
The purpose of this study is to establish the presence of an effect of treatment with ONO-2506PO in patients with Alzheimer's Disease, based upon cognitive and global scales.

Condition Intervention Phase
Alzheimer's Disease Drug: ONO-2506PO Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Effects of ONO-2506PO in Patients With Alzheimer's Disease

Resource links provided by NLM:


Further study details as provided by Ono Pharmaceutical Co. Ltd ( Ono Pharma USA Inc ):

Primary Outcome Measures:
  • Cognitive Function Scale
  • Global Function Scale

Secondary Outcome Measures:
  • ADL Scale
  • Psychiatric Symptom Scale

Enrollment: 647
Study Start Date: June 2004
Study Completion Date: July 2007
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of probable Alzheimer's Disease using NINCDS/ADRDA criteria
  • Standardized MMSE Score of 13 to 24 points (inclusive)
  • Modified Hachinski score equal or less than 4

Exclusion Criteria:

  • Serious systemic disease that may preclude survival to study completion
  • Other illnesses that may include dementive features
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00083421


  Show 87 Study Locations
Sponsors and Collaborators
Ono Pharma USA Inc
  More Information

Responsible Party: Ono Pharma USA Inc
ClinicalTrials.gov Identifier: NCT00083421     History of Changes
Other Study ID Numbers: ONO-2506POU010
First Submitted: May 24, 2004
First Posted: June 18, 2004
Last Update Posted: June 13, 2012
Last Verified: June 2012

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders